Blackstone antes $250M on its first big biotech bet, focused on a cardio drug spun out of Novartis
Five months after Blackstone bought out Clarus with a plan to dive deep into the life sciences field, the global private equity player has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
